Allakos (ALLK)
(Delayed Data from NSDQ)
$0.56 USD
+0.02 (2.98%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $0.58 +0.02 (3.57%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Allakos Inc. [ALLK]
Reports for Purchase
Showing records 1 - 12 ( 12 total )
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Advancing Lead Program Lirentelimab in Multiple Indications With Phase 2 Top-Line Data on Track for 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
Lirentelimab Program Moving Ahead in Atopic Dermatitis and Urticaria Following Phase 3 Miss in Eosinophilic Duodenitis
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Multiple Potential Positive Events to De-Risk Lirentelimab on Track for 2H22; FDA Meeting Expected in 3Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Completes Restructuring; Multiple Data Updates on Lead Program Lirentelimab Expected in 2H22 and 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Multiple Upcoming Catalysts for Dermatological Indications; EGID Programs Could Gain Traction Again Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
Lirentelimab Atopic Derm and Urticaria Programs Advancing, Deep Dive Demonstrates Potential in EGIDs; Unveils AK006
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
Following Miss in EGIDs, Lirentelimab''s Path to Rely on Atopic Dermatitis, Urticaria; PT to $20; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; Late Stage Clinical Trial Data on Track for 4Q21 or 1Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Late Stage Trial Top-Line Data on Track for 4Q21; Pipeline Expansion Expected in 2H21
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Allakos Inc.
Industry: Medical - Biomedical and Genetics
Many Billion Dollar Birds, One Stone; Initiating With a Buy and $230 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
|